PhD student “Novel radionuclide therapy agents”

Solliciteren
InloggenVacature plaatsen
Terug naar overzicht

PhD student “Novel radionuclide therapy agents”

Nu solliciteren
Vakgebied
Onderzoeker
Functie
PHd
Branche
Onbekend
Aanstelling
Niet nader bepaald
Plaatsingsdatum
21 november 2022
Niveau
Overig
Ervaring
Niet nader bepaald
Dienstverband
Niet nader bepaald

Working environment

The department of Nuclear Medicine and Molecular Imaging (NGMB) uses medical imaging techniques to make abnormalities in humans visible. These imaging techniques ("scans") use radioactively labeled tracers (radiopharmaceuticals). These scans are used, among other things, for the diagnosis of a large number of diseases, assessing the effectiveness of a treatment, drug research, and fundamental research into the processes that play a role in various diseases. In addition, substituting the diagnostic radionuclide with a therapeutical radionuclide enables the use of these radiopharmaceuticals in the treatment of patients. The NGMB department is part of the Medical Imaging Center (MIC) and subsequently, part of the University Medical Center Groningen (UMCG). The department plays an important role in high-quality patient care within the UMCG, in education, and research. In addition, the department participates in various partnerships with universities and industries at home and abroad.

Research topic: New radionuclide therapy agents against triple-negative breast cancer (TNBC)
Triple-negative breast cancer (TNBC) patients correspond to 10-25% of BC patients who do not benefit from alternative treatments when standard treatment fails. The aim of this project is to investigate whether target radionuclide therapy (TRT) can be used as an efficient alternative treatment for TNBC. The successful applicant will synthesize new novel radionuclide therapy agents including multi-step synthesis of the precursors and non-radioactive standards; perform the radiolabeling of the newly synthesized compounds and investigate the effectiveness of each new radiopharmaceutical using different models in vitro, such as different tumor cell lines and in vivo models. We are looking for an excellent, highly motivated, resilient, and independent PhD candidate with a background in Chemistry and with high knowledge of organic chemistry.




What do we need

  • You have followed a course radiation hygiene, or are willing to follow this.
  • You will receive a master's degree in a chemistry or pharmacy field.
  • You have experience in organic chemistry.
  • You are willing to work in a multi-disciplinary environment, with a high degree of cross-training.
  • You are willing to work with radionuclides.
  • You have excellent organizational skills.
  • You have excellent communication skills in English (written and oral).
  • You have experience with open source ionizing radiation, radiochemistry, and/or radionuclide therapy is a plus.

The UMCG has a preventive Hepatitis B policy. The UMCG can provide you with the vaccination, should it be required for your position.
In case of specific professions a ‘Certificate of Good Conduct’ is required.

What do we offer

You will recieve a contract for 4 years fulltime (36 hours). Your salary will be a minimum of € 2.631,- gross per month in the first year and a maximum of € 3.336,- gross per month (scale PRO) in the final (fourth) year, based on a full-time appointment. In addition, the UMCG will offer you 8% holiday pay, and 8.3% end-of-year bonus. The conditions of employment comply with the Collective Labour Agreement for Medical Centres (CAO-UMC).

For questions about the position

Any questions? Do contact us.

How to apply

Please use the the digital application form at the bottom of this page - only these will be processed.
You can apply until 12 december 2022.
Within half an hour after sending the digital application form you will receive an email- confirmation with further information.

Not your vacancy?

Check if an open application is possible for you.

Is dit uw nieuwe uitdaging?

Nu solliciteren Vacature mailen Vacature printen

PhD student “Novel radionuclide therapy agents”

Groningen
Overig
Niet nader bepaald
Niet nader bepaald
Nu solliciteren